Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-06-27

Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating reslizumab for eosinophilic asthma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • reslizumab (reslizumab)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Eosinophilic Asthma | Phase 3 | Status: COMPLETED | Results posted: 2016-06-27